基线颈动脉内膜中层厚度与普伐他汀二级预防期间卒中复发
该研究为J-STARS Echo研究的事后分析,纳入793例非心源性栓塞性卒中患者,随机接受普伐他汀10mg/日或对照组治疗5年。结果显示,在基线平均颈动脉IMT最高三分位组(≥0.931 mm)中,普伐他汀组动脉粥样硬化血栓性脑梗死风险低于对照组(P=0.045)。
要点
- 基线颈动脉IMT最高三分位(≥0.931 mm)者动脉粥样硬化血栓性脑梗死风险更高。
- 普伐他汀10mg/日可能降低最高IMT三分位患者的动脉粥样硬化血栓性脑梗死风险。
- 该获益仅在最高IMT三分位组中经log-rank检验显示(P=0.045)。
核心结论
- 长期普伐他汀治疗可能预防基线IMT最高三分位非心源性栓塞性梗死患者的动脉粥样硬化血栓性脑梗死发生。
研究设计与样本
- J-STARS Echo研究预设的事后分析,患者随机1:1接受普伐他汀10 mg/日或对照组治疗5年。
- 共纳入793例患者,普伐他汀组388例,对照组405例;基线颈总动脉平均IMT由超声测量。
主要发现
- 对照组中,基线平均IMT最高三分位组(≥0.931 mm)动脉粥样硬化血栓性脑梗死发生率高于最低三分位组(<0.812 mm),风险比9.08(95%CI 1.15-71.43)。
- 普伐他汀组动脉粥样硬化血栓性脑梗死风险低于对照组,仅在最高三分位IMT组经log-rank检验显示(P=0.045)。
关键数值与推荐
- 基线平均IMT分组:最低三分位<0.812 mm,最高三分位≥0.931 mm。
- 普伐他汀剂量为10 mg/日,治疗5年。
临床怎么用
- 对非心源性栓塞性卒中且基线颈动脉IMT较高(≥0.931 mm)的患者,可考虑长期普伐他汀10 mg/日二级预防。
- 基线IMT较低者从普伐他汀治疗中的获益在本分析中未显示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- As a prespecified post hoc analysis of the J-STARS (Japan Statin Treatment Against Recurrent Stroke) Echo Study, the 5-year stroke recurrence rate according to the baseline mean carotid intima-media thickness (IMT) with and without pravastatin treatment was investigated. Methods- Patients were randomly assigned to receive pravastatin 10 mg/day (pravastatin group) or control group (nonstatin treatment; 1:1) for 5 years. Baseline mean IMT of the common carotid artery was measured by ultrasonography. Cox proportional hazards models were used to investigate whether the stroke (any ischemic stroke, atherothrombotic brain infarction, or lacunar infarction) recurrence rate was different according to tertiles of baseline mean IMT. Results- A total of 793 patients, including 388 in the pravastatin group and 405 in the control group, were investigated. In the control group, Cox proportional hazards models showed that participants in the highest tertile IMT group (≥0.931 mm) had a higher rate of atherothrombotic brain infarction than those in the lowest tertile IMT group (<0.812 mm; [hazard ratio, 9.08; 95% CI, 1.15-71.43]). Patients in the pravastatin group had a lower risk of atherothrombotic brain infarction than those in the control group only in the highest tertile IMT group by the log-rank test ( P value=0.045). Conclusions- Long-term pravastatin administration may prevent the occurrence of atherothrombotic brain infarction in noncardioembolic infarction patients with the highest tertile IMT. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT00361530.
引用
- Wada S, Koga M, Minematsu K, et al. Baseline Carotid Intima-Media Thickness and Stroke Recurrence During Secondary Prevention With Pravastatin. Stroke. 2019. PMID: 31035902. doi:10.1161/STROKEAHA.119.024968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。